Primary retroperitoneal lymph node surgery versus chemotherapy for good‑prognosis metastatic testicular cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational comparison of two treatment pathways for men with good‑prognosis metastatic germ cell tumors: primary retroperitoneal lymph node dissection (RPLND) versus three courses of BEP chemotherapy. Participants are enrolled into a surgery group (RPLND for seminoma stage IIA–IIB with up to 2 retroperitoneal nodes each ≤30 mm) or a chemotherapy group (3–4 courses of BEP for good‑prognosis seminoma or nonseminoma). The primary outcome is change in global health‑related quality of life measured by the EORTC QLQ‑C30 plus the testicular cancer module QLQ‑TC26, with additional patient‑reported and clinician‑reported secondary outcomes including fatigue, retrograde ejaculation, and complication rates. Recruitment is population‑based across eight centers in Sweden and Norway with follow‑up planned through 2 years to capture short‑ and longer‑term effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A/B (maximum 2 nodes, \<30 mm in any dimension)
* Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, \<30 mm in any dimension)
* Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)

Exclusion Criteria:

* Previous chemotherapy (including adjuvant chemotherapy at diagnosis)
* Previous RPLND
* Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires

Where it's running

• Sahlgrenska University Hospital
  Gothenburg, Göteborg, Sweden Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sodium thiosulfate to protect hearing during cisplatin therapy in adults with solid tumors

  This study tests Pedmark sodium thiosulfate to see if it reduces hearing loss in adults receiving standard cisplatin chemotherapy.

  Recruiting Phase 1/2 University of Arizona · Tucson, Arizona · NCT07407582

• Navigation program for young cancer survivors

  This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.

  Recruiting Kaiser Permanente · Pasadena, California · NCT07406087

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

• How retroperitoneal lymph node dissection affects urination and sexual function

  This project will see if retroperitoneal lymph node dissection (RPLND) for testicular cancer changes urination, ejaculation, erections, and quality of life in adult men.

  Recruiting Jagiellonian University · Krakow, Malopolska · NCT06954233

• Primary retroperitoneal lymph node dissection for seminoma with limited retroperitoneal lymph node spread

  This trial will try surgery (retroperitoneal lymph node dissection) to treat men with pure seminoma who have one or two small (≤3 cm) retroperitoneal lymph node metastases and normal tumor markers.

  Recruiting Phase 2 Western University, Canada · London, Ontario · NCT06932458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.